Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Amesite Announces Launch of Active Shooter Preparedness App with World Renowned Expert Chris Grollnek
-
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
-
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies
-
Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences
-
Nexxen Reports Results for the Fourth Quarter and Year Ended December 31, 2023
-
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Abercrombie & Fitch Co. Reports Fourth Quarter and Full Year Results
-
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
-
BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing
-
23andMe Launches New Genetic Reports on Common Forms of Cancer
-
Ollie’s Bargain Outlet Holdings, Inc. Announces Fourth Quarter and Full-Year Fiscal 2023 Release Date and Conference Call Information
-
Kelly to Participate in the Sidoti Virtual Investor Conference
-
Aktia Bank Plc: Managers’ Transactions – Juha Hammarén
-
Aktia Bank Plc: Managers’ Transactions – Anssi Huhta
-
Aktia Bank Plc: Managers’ Transactions – Outi Henriksson
-
Form 8.3 - UK Commercial Property REIT
-
Form 8.3 - GCP Asset Backed Income Fund Ltd
-
ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
-
MIND CTI Reports Fourth Quarter and Full Year 2023 Results
-
Kamada Issues 2024 CEO Letter to Shareholders
-
Kraig Biocraft Laboratories Preparing Additional Business Investment License to Advance its Business Operations
-
Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024
-
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
-
Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability
-
Landsea Homes Announces Pricing of Secondary Common Stock Offering
-
Nominations Announced for the 2024 Canadian Screen Awards
-
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
-
Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024
-
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
-
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting
-
Presenting on the Emerging Growth Conference 68 Day 2 on March 7 Register Now
-
Global Crossing Airlines, the Nation’s Fastest Growing Charter Airline, Achieves Record Annual Revenues
-
Crosschq Ranks No. 7 on Inc. Magazine’s List of the Pacific Region’s Fastest-Growing Private Companies
-
EDAP to Present at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
-
Psyence Biomedical’s Subsidiary, Psyence Australia, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study
-
Lantronix Announces Snapdragon 8 Gen 3 Mobile Hardware Development Kit for Qualcomm 8650 System-on-Chip
-
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
-
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
-
AYR Cannabis Dispensary Celebrates Opening of Relocated Tallahassee Retail Location
-
Sibros and Cavli Wireless Announce Groundbreaking Partnership to Empower IoT Connectivity Across Automotive and Beyond
-
Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results
-
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board
-
ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors
-
Interactive Strength Inc. (Nasdaq: TRNR) to Exhibit Both CLMBR and FORME Lift at IHRSA in Los Angeles March 6-8
-
CytoSorbents to Report Fiscal 2023 Operating and Financial Results
-
iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
-
Berry Corporation Reports Fourth Quarter and Full Year 2023 Financial Results
-
Fossil Group, Inc. Announces Date for Fourth Quarter and Full Year 2023 Earnings Release and Conference Call
-
Breckenridge Brewery Channels the Luck of The Irish With Nitro Irish Stout and Go Gold Sweepstakes
-
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
